This suggests that the levels of the two anti-apoptotic genes Bcl2 and MCL1 are relatively higher in K562/HIF1α exposed to Crizotinib compared to Imatinib treatment and likely contribute to the chemoresistance to Crizotinib observed in CML cells under hypoxic conditions. The gene discussed is BCL2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.